Table 2.
Unadjusted and adjusted ORs for factors associated with bacterial STI vaccine interest
| Syphilis | Chlamydia | Gonorrhoea | |||||||||||||
| Unadjusted | Adjusted† (n=186) | Unadjusted | Adjusted† (n=188) | Unadjusted | Adjusted† (n=188) | ||||||||||
| N | OR (95% CI) |
P value | OR (95% CI) |
P value | N | OR (95% CI) |
P value | OR (95% CI) |
P value | N | OR (95% CI) |
P value | OR (95% CI) |
P value | |
| Age (continuous) | 251 | 0.98 (0.96 to 1.01) |
0.16 | 0.98 (0.94 to 1.02) |
0.33 | 252 | 0.97 (0.95 to 1.00) |
0.02* | 0.97 (0.94 to 1.01) |
0.19 | 253 | 0.98 (0.96 to 1.01) |
0.20 | 0.99 (0.95 to 1.03) |
0.60 |
| Gender and gender of typical sex partner (MSW—Ref) |
245 | 1.00 (1.00 to 1.00) |
0.23 | 1.00 (1.00 to 1.00) |
0.62 | 246 | 1.00 (1.00 to 1.00) |
0.03* | 1.00 (1.00 to 1.00) |
0.32 | 247 | 1.00 (1.00 to 1.00) |
0.08 | 1.00 (1.00 to 1.00) |
0.58 |
| MSM | 1.83 (0.92 to 3.65) |
0.09 | 1.38 (0.54 to 3.52) |
0.50 | 1.65 (0.86 to 3.19) |
0.13 | 1.70 (0.64 to 4.31) |
0.26 | 1.67 (0.86 to 3.24) |
0.13 | 1.74 (0.68 to 4.45) |
0.24 | |||
| WSM | 2.05 (0.90 to 4.71) |
0.09 | 1.02 (0.37 to 2.78) |
0.97 | 3.85 (1.55 to 9.59) |
0.00** | 2.53 (0.84 to 7.67) |
0.10 | 2.88 (1.20 to 6.95) |
0.02* | 1.88 (0.65 to 5.46) |
0.25 | |||
| WSW | 1.19 (0.29 to 4.87) |
0.81 | 0.45 (0.09 to 2.23) |
0.33 | 1.59 (0.40 to 6.33) |
0.51 | 0.89 (0.19 to 4.24) |
0.89 | 2.70 (0.56 to 13.05) |
0.22 | 1.58 (0.29 to 8.79) |
0.60 | |||
| Previously received HPV vaccine‡ | 252 | 2.92 (1.18 to 7.23) |
0.02* | 2.40 (0.74 to 7.78) |
0.14 | 253 | 2.02 (0.93 to 4.40) |
0.08 | 1.30 (0.42 to 4.01) |
0.65 | 254 | 1.81 (0.83 to 3.95) |
0.14 | 1.31 (0.43 to 3.97) |
0.64 |
| Previously received hepatitis B vaccine | 251 | 1.55 (0.86 to 2.78) |
0.15 | 1.15 (0.54 to 2.44) |
0.72 | 252 | 1.57 (0.89 to 2.78) |
0.12 | 1.48 (0.68 to 3.21) |
0.33 | 253 | 1.30 (0.73 to 2.31) |
0.38 | 1.19 (0.59 to 2.57) |
0.67 |
| Intent to engage in future positive health behaviours | 198 | 3.97 (1.31 to 12.03) |
0.02* | 2.82 (0.80 to 10.00) |
0.11 | 200 | 6.49 (2.01 to 20.98) |
0.00** | 5.94 (1.56 to 22.60) |
0.01** | 200 | 5.75 (1.88 to 17.64) |
0.00** | 5.13 (1.45 to 18.07) |
0.01** |
| Willingness to pay out of pocket | 236 | 3.43 (1.43 to 8.18) |
0.01** | 3.83 (1.29 to 11.38) |
0.02** | 237 | 2.98 (1.21 to 7.32) |
0.02* | 2.70 (0.80 to 9.06) |
0.11 | 238 | 2.99 (1.23 to 7.27) |
0.02* | 2.21 (0.69 to 7.14) |
0.18 |
*Significant at p≤0.05. **Significant at p≤0.01.
†Adjusted for all other variables listed.
‡In British Columbia, Canada, girls were eligible for publicly funded HPV vaccination in 2008 through the school-based immunisation programme, and boys became eligible for the same programme in 2017. The vaccine is also available for private purchase and may be covered by some insurance or subsidy programmes.
HPV, human papillomavirus; MSM, men who have sex with men; STI, sexually transmitted infection; WSM, women who have sex with men; WSW, women who have sex with women.